TARDBP and proteostasis deficiencies: The resulting optimized protocol may be applied for global comparative proteomic profiling of human brain tissue collected post-mortem from patients affected by TDP-43 proteinopathies i.e., amyotrophic lateral sclerosis (ALS) and fronto-temporal lobar degeneration (FTLD).